

## ► PŘEHLEDOVÉ ČLÁNKY

VLIV CÍLENÉ LÉČBY BRAF A MEK INHIBITORY NA IMUNITNÍ SYSTÉM U METASTAZUJÍCÍHO MELANOMU

9. Long GV, Lebba C, Atkinson V, et al. The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. *J Clin Oncol*. 2019;37(15\_suppl):9531-9531.

10. Nathan P, Dummer R, Long GV, et al. Melanoma and other skin tumors LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial. 2020 [cited 2020 Nov 1]. Available from: <https://doi.org/10.1016/j.annonc.2020.08.2273>.

11. Ho PC, Meeth KM, Tsui YC, et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFN $\gamma$ . *Cancer Res*. 2014;74(12):3205-3217. doi: 10.1158/0008-5472.CAN-13-3461. Epub 2014 Apr 15. PMID: 24736544; PMCID: PMC4063281.

12. Elgueta R, Benson MJ, de Vries VC, et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system. *Immunol Rev*. 2009;229(1):152-172. doi: 10.1111/j.1600-065X.2009.00782.x. PMID: 19426221; PMCID: PMC3826168.

13. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature*. 2014;513(7519):559-563. doi: 10.1038/nature13490. Epub 2014 Jul 13. PMID: 25043024; PMCID: PMC4301845.

14. Bradley SD, Chen Z, Melendez B, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. *Cancer Immunol Res*. 2015;3(6):602-609. doi: 10.1158/2326-6066.CIR-15-0030. Epub 2015 Mar 20. PMID: 25795007; PMCID: PMC4457616.

15. Koya RC, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. *Cancer Res* [Internet]. 2012 Aug 15 [cited 2023 Mar 19];72(16):3928-3937. Available from: <https://pubmed.ncbi.nlm.nih.gov/22693252/>.

16. Allegranza MJ, Rutkowski MR, Stephen TL, et al. IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors. *Cancer Res* [Internet]. 2016 May 1 [cited 2023 Mar

19];76(9):2561-2572. Available from: <https://pubmed.ncbi.nlm.nih.gov/26980764/>.

17. Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. *Clin Cancer Res*. 2015;21(7):1639-51. doi: 10.1158/1078-0432.CCR-14-2339. Epub 2015 Jan 14. PMID: 25589619.

18. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. *Sci Transl Med*. 2015;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691. PMID: 25787767; PMCID: PMC4765379.

19. Hugo W, Shi H, Sun L, et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. *Cell* [Internet]. 2015 Sep 10 [cited 2020 Feb 29];162(6):1271-1285. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26359985>.

20. Hu-Lieskovan S, Mok S, Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. *Sci Transl Med* [Internet]. 2015 Mar 18 [cited 2023 Mar 19];7(279). Available from: <https://pubmed.ncbi.nlm.nih.gov/25787767/>.

21. Hong DS, Vence L, Falchook G, et al. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. *Clin Cancer Res*. 2012;18(8):2326-2335. doi: 10.1158/1078-0432.CCR-11-2515. Epub 2012 Feb 21. Erratum in: *Clin Cancer Res*. 2012 Jul 1;18(13):3715. PMID: 22355009.

22. Callahan MK, Masters G, Pratilas CA, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. *Cancer Immunol Res*. 2014;2(1):70-79. doi: 10.1158/2326-6066.CIR-13-0160. PMID: 24416731; PMCID: PMC3883307.

23. Ebert PJR, Cheung J, Yang Y, et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. *Immunity* [Internet]. 2016 Mar 15 [cited 2020 Feb 29];44(3):609-621. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26944201>.

24. Russo J, Miotto S, Saponeri A, et al. Ultra-low dose rituximab for refractory pemphigus vulgaris: a pilot study. *Expert Opin Biol Ther* [Internet]. 2020 Feb 6 [cited 2020 Feb 9];14712598.2020.1727440. Available from: <https://www.tandfonline.com/doi/full/10.1080/14712598.2020.1727440>.

dfonline.com/doi/full/10.1080/14712598.2020.1727440.

25. Steinberg SM, Zhang P, Malik BT, et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. *Cancer Immunol Res* [Internet]. 2014 Nov 1 [cited 2020 Feb 29];2(11):1044-1050. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25183499>.

26. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. *Clin Cancer Res*. 2013;19(5):1225-1231.

27. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. *Clin Cancer Res* [Internet]. 2012 Mar 1 [cited 2020 Feb 29];18(5):1386-1394. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/22156613>.

28. Wilmott JS, Haydu LE, Menzies AM, et al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. *J Immunol* [Internet]. 2014 Mar 1 [cited 2020 Feb 29];192(5):2505-2513. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/24489105>.

29. Cooper ZA, Reuben A, Spencer CN, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *Oncoimmunology*. 2016;5(3).

30. Pieper N, Zaremba A, Leonardelli S, et al. Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. *Oncoimmunology* [Internet]. 2018 Aug 3 [cited 2020 Feb 29];7(8):e1450127. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/30221038>.

31. Jiang X, Zhou J, Giobbie-Hurder A, et al. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. *Clin Cancer Res*. 2013;19(3):598-609.

32. Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4. *Clin Cancer Res* [Internet]. 2015 Apr 1 [cited 2023 Mar 19];21(7):1639-1651. Available from: <https://pubmed.ncbi.nlm.nih.gov/25589619/>.

# Chcete číst aktuální články časopisu **ONKOLOGIE ON-LINE?**

## Řešením je ELEKTRONICKÉ PŘEDPLATNÉ

- **[www.onkologics.cz](http://www.onkologics.cz)** ČTĚTE IHED v podobě listovačky či ve formátu PDF
- **bez přihlášení/předplatného** jsou články přístupné až **po 1 roce**
- **5 čísel/rok – 660 Kč** (vč. tematických příloh)

Objednávejte  
v našem e-shopu →



[www.solen.cz](http://www.solen.cz)

